177 results about "Human leukemia" patented technology

The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

The invention discloses a method for detecting anti-CD19 chimeric antigen receptor T cell effects of inhibiting leukemia cells. The method comprises 1, mixing anti-CD19 chimeric antigen receptor T cells and leukemia cells according to a certain ratio, and transplanting the mixed cells into an immunodeficient mouse model, wherein the anti-CD19 chimeric antigen receptor T cell has an accession number of CCTCC NO: C201503, 2, carrying out immunodeficient mouse model peripheral blood cell dyeing, and 3, detecting the dyed peripheral blood cells by a flow cytometer. Human leukemia cells and leukemia cell inhibition cells are transplanted into an immunodeficient mouse model together so that effects of inhibiting different human leukemia cells can be really shown and high effectiveness and accuracy of the inhibition effect detection method are guaranteed.

The invention discloses a method for establishing a PDX (Patient Derived Xenograft) model of human blood tumor. The method comprises the steps of extracting a blood tumor cell of a patient, adding rabbit anti-human thymocyte immunoglobulin ATG (Anti-Thymocyte Globulin) and patient autologous serum, mixing, incubating and after completing the incubation, re-suspending the obtained cell and inoculating in a mouse; and feeding the inoculated mouse with CsA (Cyclosporine A) and lasting for 5-10 days starting from 2 days before the inoculation of the blood tumor cell. The method disclosed by the invention has the beneficial effects that a novel highly immunodeficient NCG mouse independently developed in China is firstly adopted to establish a human leukemia PDX model; by orally taking human thymocyte immunoglobulin pretreatment sample combined with the cyclosporine for a long term, donor-derived T cells are removed and inhibited; and by combining the toxic effect of the ATG on lymphocytes with the functional blocking effect of the CsA on T lymphocytes, the immune function of the T lymphocytes can be persistently inhibited and the success rate of PDX modeling of the blood tumor is significantly improved.

The invention provides berbamine citrate. Berbamine free alkali is taken as a raw material, and edible strong organic acid is applied to substitute the prior commonly-used inorganic acid to perform a salt-forming reaction according to certain proportion at room temperature to obtain the berbamine citrate. The berbamine citrate has remarkable killing effect on various hematological tumor cells cultured in vitro such as human leukemia, multiple myeloma, lymphoma and so on, and also has remarkable inhibition effect on the growth of human hematological tumor cells in the bodies of nude mice, but the berbamine citrate with the same concentration has no remarkable effect on the cell growth of normal persons and has no remarkable toxic side effect on the nude rice; and the berbamine citrate can form a pharmaceutical composition with other optional known anti-tumor medicines with one or more therapeutically effective amounts to achieve the synergistic effect. Therefore, the berbamine citrate can be applied to the preparation of medicines for treating hematological tumor diseases.

The invention relates to 1,3-substituted-5-acetaminoindolone compounds and an application thereof to anti-tumor drugs. The compounds are 1-methyl-5-acetamino-2-indolinone, 1-(4-bromobenzyl)-5-acetamino-2-indolinone, 1-(4-methylbenzyl)-3-oxime-5-acetaminoindolone, 1-(4-methoxybenzyl)-3-oxime-5-acetaminoindolone and the like. The in-vitro tumor cell inhibitory activities of the 1,3-substituted-5-acetaminoindolone compounds synthesized in the invention are tested and the results show that such kind of compounds have certain inhibiting effects (IC50(100mu M)) on human leukemia cells (K562), human colon cancer cells (HT-29) and human liver cancer cells (HepG2), have anti-tumor activities and can be used for preparing anti-tumor drugs.

The invention discloses an S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound, a preparation method and application thereof. The compound has a structural general formula shown as formula I. The S-(5-substituted-1, 3, 4-thiadiazole)-(5-substituted phenyl)-2-furancarbothioic acid ester compound has an obvious control effect on potato late blight, cucumber fusarium wilt, Botrytis cinerea Pers, Pepper Phytophthora blight, rice sheath blight, wheat scab, Colletotrichum musae, asparagus stem blight and the like, and can be used as an agricultural fungicide in control of plant diseases. At the same time, the compound has an inhibitory effect on HL-60 human leukemia cells, MCF-7 human breast cancer cells, BGC-823 human gastric cancer cells, Bel-7402 human hepatocellular carcinoma cells, and KB human nasopharyngeal carcinoma cells, etc., and has application prospects in the aspect of anti-tumor activity. (formula I).

The invention relates to an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is 3-beta-acetoxy-ursolic alkyl-12-alkene-28-acyl (8'-aminobutyric acid) or 3-beta-acetoxyl-ursolic alkyl-12-alkene-28-acyl (4'-aminobutanol). The preparation method comprises the following steps of: converting ursolic acid into coarse 3-O-acetyl ursolic alkyl-28-acyl chloride intermediates via two steps, and making the coarse products as one of reactants react with 8-amino octanoic acid or 4-amino butanol, thereby obtaining the ursolic acid derivative. The ursolic acid derivativehas good effects on inhibition of human leukemia U937 cell proliferation, which cannot be realized by the prior art. The synthesis reaction steps in the technical scheme are reduced, the purificationmethod is simple, the cost can be reduced, and the product purity is high.

The invention discloses the application of cyclocarya paliurus extract in the preparation of a medicament for preventing and treating leukemia. High-content cyclocarya paliurus extract is obtained by performing the purification treatment combined of water extraction, ethanol extraction, membrane dialysis, and gel chromatographic column on cyclocarya paliurus leaves. The cyclocarya paliurus extract contains 90 to 98 percent of polysaccharide; killing activity detection experiments show that the cyclocarya paliurus extract can be used for improving the activity of the splenocytes for killing human leukemia cells K652 in vitro; the killing multiples can reach 2.47 to the maximum. After granules, tablets, buccal tablets, capsules, pills, powder injection or oral liquid prepared by adding certain additives into the cyclocarya paliurus extract disclosed by the invention are orally taken, the effects of preventing and treating the leukemia can be achieved.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and / or human breast cancer cell.

The invention discloses a reverse transcription-polymerase chain reaction (RT-PCR) primer of a human leukemia fusion gene BCR-ABL, which is characterized in that nucleotide sequence of the primer is: BCR_exF: 5'-TTCCGCTGACCATCAATAAG-3'; ABL_exR: 5'-CGCATGAGTTCATAGACCTT-3'; ABL_inF: 5'-CGAGTTGGTTCATCATCATTCA-3'; and ABL_inR: 5'-CCTTCTCTAGCAGCTCATACA-3'. The invention further discloses method for performing RT-PCR by using the human leukemia fusion gene BCR-ABL, a pure single reverse transcription product can be obtained according to the method, a nested polymerase chain reaction is used to achieve qualitative detection of existence of the BCR-ABL and amplify segments used for detecting sequence and containing fourteen common ABL kinase point mutational sites, and the method can remarkably improve amplification success rate of the human leukemia fusion gene BCR-ABL.

The invention provides an inula wissmannian extract and preparation thereof and application in preparation of an antitumor drug. The extract is gemma alkane type sesquiterpene lactone inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone. The extract has the following chemical structural formula and absolute configuration that: due to the toxicity killing function experiment of inula wissmannian lactone methyl, ethyl, propyl, butyl and amyl or sheepear inula herb lactone on human hepatoma cells HepG2, human prostatic cancer cells PC-3, human gastric carcinoma cells MGC-803, human leukemia cells K562, human nasopharynx cancer cells KB and normal human hepatocytes LO2, the result shows that the gemma alkane type sesquiterpene lactone has strong tumor cell killing function, and proliferation of tumor cells can be inhibited, so that the tumor cells are killed. The animal in-vivo experiment proves that the inula wissmannian plant extract and monomeric compounds have the anti-tumor effect and can serve as active ingredients for preparing the antitumor drug. A novel cancer treatment medicine is provided clinically, and high clinical application values and social benefits are generated.

In this patent, we isolated a novel compound from fruiting body of Antrodia cinnamomea, namely, (22R)-5α-lanosta-8,24-dien-3β,15α,21-triol. This compound possesses preferential cytotoxicity against human leukemia, pancreatic cancer, esophageal cancer, hepatoma, and cervical cancer cells.

The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor / Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein / GTPase Activating / Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair / RNA Binding / Transcription proteins, Serine / Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation / Transporter proteins.

The invention relates to novel water-soluble polyethylene glycol link-coupled hydroxycamptothecine derivatives and the application thereof. The general molecular formula is MPEG-X-H or H-X-PEG-X-H, wherein X refers to the linking group, such as valine, and H refers to the medicine molecule, such as hydroxycamptothecine and the like. The invention further relates to the synthesis of the prodrug and the release of the active compound under the condition of a 37-degree phosphate buffer solution. The synthetic compounds are adopted to conduct the test of tumor cells in vitro inhibitory activity against human leukemia cells (K562), human colon cancer cells (HT-29) and human hepatoma carcinoma cells (HepG2); the results show that the compounds have remarkable antitumor activity, and the data show that the release rate and in vitro activity of hydroxycamptothecine are closely related to the length of PEG connected and the connection manner. The compounds have wide prospects in development and application of antitumor drugs.

The invention relates to indolone derivatives having different positions substituted and an application thereof, and particularly relates to preparation of the indolone derivatives having the different positions substituted and the application of the indolone derivatives in preparation of anti-tumor drugs, wherein in the structural formula, R1 is one of benzyl or alkyl compounds, R2 is one of hydrogen or halogen or aryl compounds, R3 is one of hydrogen or halogen or aryl or five-membered heterocyclic or six-membered heterocyclic compounds, R4 is one of hydrogen or halogen or aryl compounds, and R5 is one of hydrogen or halogen or aryl compounds. The indolone derivatives having the different positions substituted are synthesized for the first time, anti-tumor activity tests of the synthesized compounds aiming at human hepatoma cells (HepG2), human leukemia cells (K562) and human colon cancer cells (HT-29) are performed, and results show that IC50 of the derivatives is less than 10 [mu]M.

The invention relates to a lactucin derivative, and a preparation method and application thereof. The lactucin derivative is synthesized by performing structural modification on lactucin which is separated from Cichorium glandulosum Boiss. et Huet and is taken as a parent compound. The activity result of the derivative shows that: the derivative has better effects of inhibiting A549 human lung cancer cells, HL-60 human leukemia cells, Bel-7402 human liver cancer cells and KB human nasopharyngeal darcinoma cells; meanwhile, the derivative is independent or combined with one or more pharmaceutically acceptable, inert and nontoxic excipients or carriers to form a medicinal composition to be applied to the development of antitumor medicines.

The present invention discloses 10-alkoxy camptothecinie derivatives and its preparation process and application in treating tumor. The compounds have extraneous antitumor activity in different degree to P388 human leukemia cell, A649 human lung cancer cell, PC-3 human prostate cancer cell, HO-8910 human oophoroma cell, and K562 and HL60 human leukemia cell. The experiment of inoculating naked mouse with transplanted PC-3 human prostate cancer cell and inoculating mouse with S180 malignant solid tumor shows that partial compounds possess powerful tumor inhibiting activity.

This invention discloses a method for producing liver cells by inducing haemopoietic stem cells in vitro, comprising: inoculating the haemopoietic stem cells or CD34+ cells into the culture media containing embryonic bovine serum, human stem cell factor, human interleukins 3(IL-3), interleukins 6(IL-6), human liver cell growth factor, human epidermal growth factor(EGF), human acdic fibroblast growth factor, human basic fibroblast growth factor(bFGF), human leukemia inhibitory factor(LIF) and oncostatin M(OSM), and inducing the producing of liver cells in vitro. By applying the method of this invention to induce liver cells from the haemopoietic stem cells, it can acquire a high proportion of liver cells in the culture with good effects.

The invention relates to an alkaloid with anticancer activity, which is separated from Asclepiadaceae Cynanchum per nnial herb Cynanchum Komarrovii, in particular to the alkaloid with anticancer activity and a preparation method and application thereof. The alkaloid is mainly 3 compounds: Antofine, 14-hydroxyantofine, delta 11,12-antofine, the proportion of the three alkaloids in active sites of alkaloid is 65-80%, and the proportion among the three alkaloids is 35-45%:35-45%:10-25%. The invention provides the phenanthroindolizidine alkaloids with the anticancer activity, and the evaluation of activity by an in vitro antineoplastic activity screening system discovers that the phenanthroindolizidine alkaloids provided by the invention can effectively inhibit the growth of BEL-7402 human hepatoma cells, A549 human lung carcinoma cells and MOLT-4 human leukemia cells. As a wild plant resource, the effects of windbreak and sand fixation of the Cynanchum Komarrovii can be unaffected when in use.

Provided are phenanthroindolizidine alkaloid derivates and salt thereof as well as preparation, a plant-virus resisting activity, and an anti-cancer activity of phenanthroindolizidine alkaloid derivates and salt thereof. The derivates and the salt thereof have a good plant-virus resisting activity, which is capable of well restraining a tobacco mosaic virus (TMV), and meanwhile, have a good anti-cancer activity, which is capable of well restraining the human lung adenocarcinoma A-549 and the human leukemia HL-60.

The invention relates to a pyrroloquinolines compound and an application thereof. A pyrroloquinoline ring is taken as a matrix and is appropriately and chemically modified to obtain a series of pyrroloquinolines compounds. Preliminary in vitro screen discovers that the pyrroloquinolines compound provided by the invention has a different-degree proliferation inhibition function on multiple tumour cell strains including human cervical cancer cell strain (HeLa), human lung cancer cell strain (A549), human colon cancer cell strain (HCT116), human leukemia cell strain (K562), human breast cancer cell strain (MCF-7) and the like; and moreover, the proliferation inhibition function of most compounds in 5 tumour cells is obviously better or is equivalent to a positive control drug SAHA (N-hydroxy-N'-phenyloctanediamide).

The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking / inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.

This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders / conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

The invention provides a novel resveratrol amide derivative for stopping tumor cells from multiplication. A general formula is shown in the specification, wherein the R refers to the novel resveratrol amide derivative has obvious restraining effect to epidermal cancel cell strains (KB) of the oral cavity of a human body and cell strains (K562) of human leukemia, thereby being capable of being used for preparing antineoplastic drug. The invention also discloses the preparation method of the novel resveratrol amide derivative.

The invention discloses a human leukemia HL-60 cell drug-resistance cell line HL-60 / RS cell and a preparation method thereof. The preservation number of the cell line HL-60 / RS is CCTCC No. C201430. The preparation method is characterized in that a human leukemia HL-60 cell line is used as a parent cell, adriamycin is used for simulating an internal chemotherapy process, and a gradual long-term intermittent repeated drug concentration impact increasing and continuous induction method is used for establishing the leukemia multidrug-resistance cell line HL-60 / RS. The preparation method has the beneficial effects that the leukemia multidrug-resistance cell line HL-60 / RS is established by adopting the concentration impact increasing and continuous induction method, and experiments prove that the established drug-resistance cell line has the characteristics of wide drug-resistance spectrum, stable drug resistance and the like; the drug-resistance cell line has high drug resistance and can be used for researching the sensitivity, drug resistance and arsenic resistance of tumor cells to anti-cancer drugs and screening resistance-reversal agents with reliability.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and / or human breast cancer cell.

The invention relates to the technical field of medicines, in particular to 16 cytospolides A-P which are separated from a plant endophytic fungus cytospora sp. fermentation product and have anti-tumor and antibacterial activity. The in-vitro anti-tumor test proves that the cytospolides A-P have the effect of obviously inhibiting HCT116 (human colon cancer cells), A549 (human lung cancer cells), QGY-7703 (human liver cancer cells), A375 (human melanoma cells), and U937 (human leukemia cells) tumor cell strains; and the in-vitro antibacterial test proves that the cytospolides A-P have the effect of obviously inhibiting microbotryum violaceum, septoria tritici, Escherichia coli and bacillus megaterium. Therefore, the cytospolides A-P can be used for preparing anti-tumor or antibacterial medicines, are novel lead compounds for developing the anti-tumor and antibacterial medicines, and have great significance for developing and utilizing plant endophyte resources.

The invention provides an antitumor medicament with combination of spirulina polysaccharide and ginkgo-leaf effective components, which relates to an antitumor medicament. The antitumor medicament is formed by combining spirulina polysaccharide and ginkgo-leaf effective components, wherein the mass ratio of the spirulina polysaccharide to the ginkgo-leaf effective components is 0.35-1.5:0.35-1.5; the optimal mass ratio of the spirulina polysaccharide to the ginkgo-leaf effective components is 1:1; the spirulina polysaccharide is a water-soluble complex heteropolysaccharide, has the polysaccharide content more than or equal to 93 percent, is formed mainly by connecting D-mannose, D-glucose, D-galactose and glucuronic acid through alpha-type glycosidic bonds, and has the molecular weight of about 12,590 D; and the ginkgo-leaf effective components have the total-flavonoid content more than or equal to 24 percent and the terpene-lactones content more than or equal to 6 percent. The medicament has remarkable tumor-inhibiting effect on S180 sarcoma growing in vivo, as well as human colon cancer HT29 cells, human leukemia HL60 cells, human gastric cancer MGC cells, human cervical carcinoma HeLa cells, human hepatoma 7402 cells and human breast cancer cells growing in vitro.

The invention provides a histone deacetylases (HDACs) inhibitor compound N<1>-(6-(hydroxyamino)-6-oxohexyl)-N<4>-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)terephthalamide having an obvious inhibitory effect on both HDACs and human leukemia U937 cell growth and proliferation, wherein the inhibitory effect is significantly stronger than that of a common HDACs inhibitor trichostatin TSA. The invention also provides a preparation method and a process route of the compound.